Technology Platforms

Disruptive technologies, genomics, and artificial intelligence have unleashed a flood of innovation. Welcome to a new era in drug discovery.
Illustration of natural killer (immune) cells checking for cells that don’t belong
Illustration of natural killer (immune) cells checking for cells that don’t belong
Our incredibly talented, creative scientists dig into a rich toolbox of technologies to develop smart, safe, effective medicines and vaccines that break the mold.
Matt Truppo

Matt Truppo

Head of Global Research Platforms

Research-Enabling Technologies

Technologies are part of our rich ecosystem, which is built on patient insights, lasting alliances, and a unique capacity to deliver for patients and communities everywhere.

SYNTHORIN™ Molecules

By expanding the genetic alphabet, we can design and optimize protein-based treatments in ways that were previously impossible. 

Antibody-Drug Conjugates

We’re designing antibodies that act like a GPS, guiding anti-cancer drugs to a protein on tumor cells. 

Natural Killer Cells

The precision of natural killer cells helps us create new immunotherapies to help the body fight cancer. 

Genomic Medicine

Our integrated genomic medicine unit is accelerating progress toward gene and cell therapies by combining an array of techniques, from nucleic acid nanostructures to viral and non-viral gene-delivery platforms.

Artificial Intelligence

Our partnerships with leading-edge data science companies Owkin and Exscientia give our teams access to unique AI platforms.

NANOBODY® Molecules

At a tenth the size of conventional antibodies, NANOBODY® molecules have the potential to reach disease targets in the human body that are inaccessible to conventional antibodies. 


With this revolutionary chemistry, a "double lock and key" mechanism makes it possible to design small molecules with limited ability to interact with off-target molecules. 


mRNA carries messages that instruct cells to make proteins, which stimulates the immune system to produce antibodies. We are using mRNA in our research to develop vaccines and to address long-standing challenges in cancer, immune-mediated diseases, and rare diseases.

The possibilities for implementing and combining technologies are endless. Our work is extremely collaborative. A scientist at the bench with an idea can reach out to colleagues with disease area knowledge, protein engineering expertise, or machine learning skills, to follow the concept through and test it out. It’s empowering!
Rebecca Sendak

Rebecca Sendak

Global Head of Large Molecules

Monoclonal Antibodies

Rather than stimulating the body to produce its own antibodies, we can design monoclonal antibodies to offer immediate protection against certain diseases. This kind of rapid protection could bridge important gaps in immunity, especially among very young infants and other at-risk populations. We use monoclonal antibodies in our immunization for infants to combat RSV.

Inactivated Vaccines

Inactivated vaccines use the killed version of disease-causing germs. Polio, rabies, and most influenza vaccines are based on lab-cultured, inactivated or killed viruses.

Antibody Engineering

Our exclusive access to IGM Bio’s immunology platform lets us create, develop, manufacture, and commercialize a new class of antibodies that could overcome the limitations of conventional IgG antibodies.

Multi-Specific Antibodies

Proprietary technologies allow our teams to develop antibodies that recognize two or three different targets. By combining key features of several different antibodies into a single therapy, we can tackle cancers and immunological disorders on multiple fronts.

siRNA Conjugates

RNA interference helps us slow the production of disease-causing proteins. We’re collaborating with Alnylam to harness this natural process in new therapies for rare blood disorders.

Protein Degraders

We’re collaborating with Kymera and Nurix to develop advanced protein degrader therapies for people with challenging diseases.

Conditional Biologics

Proprietary “masking” technology helps us develop immunotherapies that overcome long-standing challenges with T-cell engagers.

Explore More

Work With Us

Partner With Us

Scientific Collaboration

Page updated February 2024

MAT-GLB-2100354 v4.0 02/2024